CCL22 KO mice have not been analyzed, but clinical indicators suggest involvement in MS pathogenesis in women (69, 76). Administration of anti-CCL22 at the time of autoantigen immunization delayed the initiation of clinical disease (77). Here, CCL22 is linked to myeloid sarcoma.